facebook button EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with olaparib
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with olaparib

Sponsor: Ellipses Pharma

A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance